Objectives. To evaluate haemophilia patients' knowledge and understand
ing of factor concentrate products and to assess their feelings regard
ing purity and viral safety of these products. Methods. Sixty question
naires were distributed and completed by patients or parents of patien
ts with severe/moderate haemophilia A at two large comprehensive haemo
philia centres in the USA and Italy. Results. Most patients knew what
brand of factor concentrate they used, but less than half were aware o
f how their concentrate was virally inactivated. The majority of respo
nders perceived recombinant factor VIII as being the concentrate with
the highest degree of purity. The majority felt the decision of which
concentrate to use should be the care-givers not the patients. Conclus
ions. It appears that patients need more education concerning the conc
entrate they are using, and its method of viral inactivation and purit
y.